Mumbai, India, 11 November 2021 – Purple MicroPort Cardiovascular Private Limited (Purple MicroPort), an Indian joint venture company of MicroPort Scientific Corporation (MicroPort®) has officially launched for commercial sale the Firehawk IN™ Rapamycin Target Eluting Coronary Stent System (Firehawk IN™) for the Indian drug eluting stent (DES) market. Manufactured in Purple MicroPort’s facility in Gujarat, India, Firehawk IN™ is the first drug eluting stent product MicroPort has manufactured in India.
Firehawk IN™ is a target eluting stent combining the merits of a bare metal sent and a DES. As the world's low drug dosage stent, Firehawk IN™ adopts a unique, proprietary, in-groove abluminal coating design and target-eluting technique, which allows Firehawk IN™ to achieve the clinical efficacy and safety with a significantly lower drug load, which benefits patients by promoting early vascular healing.
With all local regulatory approvals obtained and manufacturing and quality control processes successfully completed, Purple MicroPort has commenced the commercial launch of Firehawk IN™ on 4th of November 2021 – the auspicious holiday of Deepavali, the festival of lights. Purple MicroPort will commercially launch Firehawk IN™ in a few key hospitals which will follow full India market availability of Firehawk IN™ by 1st January 2022.
“In 2017, MicroPort® first entered the Indian market with Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®). In 2020, MicroPort® formed our joint venture called Purple MicroPort which strengthened our local India commercial and manufacturing capabilities,” stated Jonathan Chen, Chief International Business Officer of MicroPort®, “Now in 2021, with the launch of Firehawk IN™ in India this will allow us to further penetrate an important, long-term, strategic market, the India DES market which will be the second largest number of PCI cases in the world by the end of this decade.”
“MicroPort®’s coronary products represented by the Firehawk® family of stents have a safety and quality comparable to that of international high-market share stent products, and have a large body of clinical data that show favorable results compared to the leading drug eluting stents in the world,” noted Brian Lancelot, CEO of Purple MicroPort, “We are confident that Firehawk IN™ can be utilized by Indian interventional cardiologists to treat patients with coronary artery disease, and we are committed to partner with local medical communities through academic activities such as evidence-based medicine and professional education to support this launch.“
Purple MicroPort is poised to become a leading provider of innovative medical devices in the Indian market by leveraging MicroPort®’s global product portfolio, combined with Purple Medical’s strong local business channels and manufacturing expertise.
About Purple MicroPort
Established in June 2020 in India, Purple MicroPort Cardiovascular Private Limited (Purple MicroPort) is the local medical devices engine of MicroPort Scientific Corporation (MicroPort®, Stock code: 00853.HK), a global leading medical devices company founded in Shanghai China, and Purple Medical Solutions Private Limited, one of the top five domestic manufacturers in the Indian market for drug-eluting stents. Purple MicroPort is dedicated to helping improve the local medical level through evidence-based medicine, clinician education and academic activities with global leading products and technology. Our close collaboration with doctors and medical societies in India helps us accelerate innovation and develop solutions to transform medical treatment.
About MicroPort®
Founded in Shanghai in 1998 on the belief that every person has the right to high quality medical treatments, MicroPort Scientific Corporation (MicroPort®, Stock code: 00853.HK) is today a global medical devices company with over 9,000 employees worldwide. We provide solutions across twelve therapeutic areas, including orthopedics, cardiac rhythm management, electrophysiology and endovascular. At MicroPort®, we are breaking barriers and accelerating access to life-changing solutions with the purpose of prolonging and reshaping the lives of patients everywhere. Our therapeutic solutions are available in more than 80 countries and over 10,000 hospitals around the world, and today, a patient benefits from a MicroPort® solution every six seconds.